Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Sales of Investments
Cash received from selling or redeeming investments.
Gossamer Bio, Inc.NASDAQ: GOSS
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $66.6M fell 45.9% year over year, behind the -34.5% change in trailing-twelve-month sales of investments. Sequentially, it fell 29.3% from the prior quarter. Over 3 fiscal years it compounded at +17.3% a year.
Context
- Sales of investments amounted to 791.3% of revenue in FY2025, up 334.6 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -45.9% toward the trailing-twelve-month pace of -34.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 383.54M USD
- Year-over-year change
- -26.8%
- 4-year CAGR
- +80.4%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 383.54M | -26.8% |
| FY2024 | 2024-12-31 | 523.8M | +58.4% |
| FY2023 | 2023-12-31 | 330.7M | +39.2% |
| FY2022 | 2022-12-31 | 237.5M | +555.6% |
| FY2021 | 2021-12-31 | 36.23M | — |
Sales of Investments vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 sales of investments of $327.04M is the 2nd largest of the 9 companies compared; the peer median is $136.06M.
- Its year-over-year change of -34.5% is the 6th highest of 7, against a peer median of +4.4%.
- Sales of investments amounts to 588.9% of revenue for GOSS, versus a peer median of 146.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $335.91M | +15.0% | +16.1% | 382.5% | |
| LTM Mar 2026 | $327.04M | -34.5% | +17.3% | 588.9% | |
| LTM Mar 2026 | $321.66M | -6.3% | +4.1% | — | |
| LTM Mar 2026 | $286.12M | -10.8% | +33.3% | 324.2% | |
| LTM Mar 2026 | $183M | -47.3% | +57.9% | 262.8% | |
| LTM Mar 2026 | $89.12M | +78.3% | +24.9% | — | |
| LTM Mar 2026 | $65.97M | +55.1% | -15.5% | 22.0% | |
| LTM Dec 2025 | $34.88M | — | — | 30.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GOSS) | $136.06M | +4.4% | +20.5% | 146.4% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 32.01M | 42.55M | 28.52M | 20.62M | 10.56M |
| Change in Working Capital | 774K | (4.46M) | (14.84M) | 39.46M | (13.63M) |
| Accounts Receivables | 0 | 0 | 0 | (5.34M) | (6.89M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.43M) | (1.81M) | 3.99M | (1.66M) | (2.75M) |
| Other Working Capital | 5.2M | (2.65M) | (18.83M) | 46.45M | (3.99M) |
| Other Non-Cash Items | 7.17M | (177K) | 2.6M | (11.17M) | 1.18M |
| Operating Cash Flow | (188.89M) | (187.03M) | (159.16M) | (3.47M) | (171.27M) |
| Capital Expenditures | (1.62M) | (475K) | 0 | 0 | (79K) |
| Acquisitions (Net) | 0 | (65K) | 0 | 0 | 0 |
| Purchases of Investments | (152.03M) | (238.06M) | (441.67M) | (494.78M) | (227.11M) |
| Sales of Investments | 36.23M | 237.5M | 330.7M | 523.8M | 383.54M |
| Other Investing Activities | (75K) | 65K | 0 | 0 | 0 |
| Investing Cash Flow | (117.43M) | (1.04M) | (110.97M) | 29.02M | 156.36M |
| Debt Repayment | 0 | (5.81M) | (11.61M) | (12.58M) | 0 |
| Common Stock Issued | 0 | 119.95M | 201.32M | 464K | 6.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 629K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.33M | 2.95M | 444K | 0 | 0 |
| Financing Cash Flow | 3.33M | 117.09M | 190.15M | (11.49M) | 6.43M |
| Effect of Forex Changes | (165K) | (517K) | 110K | (102K) | 141K |
| Net Change in Cash | (303.15M) | (71.49M) | (79.86M) | 13.97M | (8.34M) |
| Free Cash Flow | (190.51M) | (187.51M) | (159.16M) | (3.47M) | (171.35M) |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.